Skip to main content

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.15
+1.59 (0.76%)
AAPL  273.10
+0.96 (0.35%)
AMD  213.65
-0.19 (-0.09%)
BAC  51.24
+0.83 (1.65%)
GOOG  311.83
+0.91 (0.29%)
META  649.62
+10.32 (1.61%)
MSFT  398.77
+9.77 (2.51%)
NVDA  195.57
+2.72 (1.41%)
ORCL  151.34
+5.20 (3.56%)
TSLA  413.95
+4.57 (1.12%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.